Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2024 Jul 2

PMID 38954413

Authors

Leila Hashemi

Andriana Marijic Buljubasic

Matthew J Budoff

Laurel A Copeland

Nicholas J Jackson

Guneet K Jasuja

Jeffery Gornbein

Karen Reue

Affiliations

Soon will be listed here.

Abstract

Importance: Gender-affirming hormone treatment (GAHT) is a common therapy for transgender individuals to reduce gender dysphoria and improve quality of life. Clarifying the long-term effects of GAHT remains a priority in transgender health research.

Objective: To explore whether sex hormones (estradiol and testosterone) are associated with the development of metabolic syndrome in transgender veterans compared with cisgender veterans.

Design, Setting, And Participants: This retrospective, longitudinal cohort study used International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes for gender dysphoria from the Veterans Health Administration national database to identify transfeminine and transmasculine veterans receiving documented feminizing (estradiol) or masculinizing (testosterone) treatment from January 1, 2006, to December 31, 2019, and for whom the GAHT initiation date and metabolic syndrome component-related data were available. Transgender veterans were matched to cisgender referents.

Exposure: Gender-affirming hormone treatment.

Main Outcomes And Measures: Metabolic syndrome z-scores were calculated based on body mass index, systolic blood pressure, and levels of high-density lipoprotein cholesterol, triglycerides, and blood glucose. Changes in mean z-scores were compared among the transgender and cisgender groups before and after the index date (corresponding to GAHT initiation) using a repeated-measures analysis of variance model.

Results: The cohort included 1290 participants: 645 transgender (494 [38.3%] transfeminine, 151 [11.7%] transmasculine) and 645 cisgender (280 [21.7%] female, 365 [28.3%] male). Mean (SD) age at the index date was 41.3 (13.2) years. Metabolic syndrome z-scores changed significantly over time and differed significantly across groups. Overall, transmasculine veterans had the greatest percentage increase in mean (SEM) z-scores after vs before the index date (298.0% [57.0%]; P < .001), followed by cisgender females (108.3% [27.5%]; P < .001), cisgender males (49.3% [27.5%]; P = .02), and transfeminine persons (3.0% [10.7%]; P = .77).

Conclusions And Relevance: In this cohort study, in both cisgender and transgender veterans, estradiol was associated with reduced metabolic syndrome risk, whereas testosterone was associated with increased risk. However, transmasculine individuals had the greatest risk and transfeminine individuals had the lowest risk of metabolic syndrome associated with these hormones. This is relevant for the management of metabolic syndrome risk factors in cisgender and transgender individuals and to potentially predict the risk of atherosclerotic cardiovascular disease, type 2 diabetes, systolic hypertension, insulin resistance, and nonalcoholic fatty liver disease.

Citing Articles

Cross-Sex Hormone Therapy Is Associated With Loss of Circadian Rhythm in the Male Rat.

Mallette J, Crudup B, Oudomrath Speyrer A, Rawls A, Cockrell K, Willis A Hypertension. 2024; 82(2):241-254.

PMID: 39633591 PMC: 11735301. DOI: 10.1161/HYPERTENSIONAHA.124.23901.

Doing Justice: Ethical Considerations Identifying and Researching Transgender and Gender Diverse People in Insurance Claims Data.

Alpert A, Babbs G, Sanaeikia R, Ellison J, Hughes L, Herington J J Med Syst. 2024; 48(1):96.

PMID: 39394534 PMC: 11469973. DOI: 10.1007/s10916-024-02111-w.

References

Jones M, Boon W, McInnes K, Maffei L, Carani C, Simpson E . Recognizing rare disorders: aromatase deficiency. Nat Clin Pract Endocrinol Metab. 2007; 3(5):414-21. DOI: 10.1038/ncpendmet0477. View

Martin S, Blaha M, Elshazly M, Brinton E, Toth P, McEvoy J . Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013; 62(8):732-9. DOI: 10.1016/j.jacc.2013.01.079. View

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2008; 4(4):198-203. DOI: 10.1097/00132577-200512000-00018. View

Witte M, Resuehr D, Chandler A, Mehle A, Overton J . Female mice and rats exhibit species-specific metabolic and behavioral responses to ovariectomy. Gen Comp Endocrinol. 2010; 166(3):520-8. PMC: 2856744. DOI: 10.1016/j.ygcen.2010.01.006. View

Tenenbaum A, Fisman E . "The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol. 2011; 10:11. PMC: 3036609. DOI: 10.1186/1475-2840-10-11. View

DeBoer M, Gurka M . Ability among adolescents for the metabolic syndrome to predict elevations in factors associated with type 2 diabetes and cardiovascular disease: data from the national health and nutrition examination survey 1999-2006. Metab Syndr Relat Disord. 2010; 8(4):343-53. PMC: 3046372. DOI: 10.1089/met.2010.0008. View

Morgan R, Teal C, Reddy S, Ford M, Ashton C . Measurement in Veterans Affairs Health Services Research: veterans as a special population. Health Serv Res. 2005; 40(5 Pt 2):1573-83. PMC: 1361220. DOI: 10.1111/j.1475-6773.2005.00448.x. View

Eshtiaghi R, Esteghamati A, Nakhjavani M . Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas. 2009; 65(3):262-6. DOI: 10.1016/j.maturitas.2009.11.004. View

Zhang H, Sairam M . Sex hormone imbalances and adipose tissue dysfunction impacting on metabolic syndrome; a paradigm for the discovery of novel adipokines. Horm Mol Biol Clin Investig. 2014; 17(2):89-97. DOI: 10.1515/hmbci-2014-0002. View

10.

Auer M, Cecil A, Roepke Y, Bultynck C, Pas C, Fuss J . 12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study. Sci Rep. 2016; 6:37005. PMC: 5105120. DOI: 10.1038/srep37005. View

11.

Wolfe H, Reisman J, Yoon S, Blosnich J, Shipherd J, Vimalananda V . Validating Data-Driven Methods for Identifying Transgender Individuals in the Veterans Health Administration of the US Department of Veterans Affairs. Am J Epidemiol. 2021; 190(9):1928-1934. DOI: 10.1093/aje/kwab102. View

12.

Meerwijk E, Sevelius J . Transgender Population Size in the United States: a Meta-Regression of Population-Based Probability Samples. Am J Public Health. 2017; 107(2):e1-e8. PMC: 5227946. DOI: 10.2105/AJPH.2016.303578. View

13.

Ferrannini E, Haffner S, Mitchell B, Stern M . Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991; 34(6):416-22. DOI: 10.1007/BF00403180. View

14.

Zhang Q, Goodman M, Adams N, Corneil T, Hashemi L, Kreukels B . Epidemiological considerations in transgender health: A systematic review with focus on higher quality data. Int J Transgend Health. 2020; 21(2):125-137. PMC: 7430478. DOI: 10.1080/26895269.2020.1753136. View

15.

Gurka M, Filipp S, Musani S, Sims M, DeBoer M . Use of BMI as the marker of adiposity in a metabolic syndrome severity score: Derivation and validation in predicting long-term disease outcomes. Metabolism. 2018; 83:68-74. PMC: 5960618. DOI: 10.1016/j.metabol.2018.01.015. View

16.

Bardsley M, Falkner B, Kowal K, Ross J . Insulin resistance and metabolic syndrome in prepubertal boys with Klinefelter syndrome. Acta Paediatr. 2011; 100(6):866-70. PMC: 4164507. DOI: 10.1111/j.1651-2227.2011.02161.x. View

17.

Bianchi V, Locatelli V . Testosterone a key factor in gender related metabolic syndrome. Obes Rev. 2018; 19(4):557-575. DOI: 10.1111/obr.12633. View

18.

Link J, Chen X, Prien C, Borja M, Hammerson B, Oda M . Increased high-density lipoprotein cholesterol levels in mice with XX versus XY sex chromosomes. Arterioscler Thromb Vasc Biol. 2015; 35(8):1778-86. PMC: 4668127. DOI: 10.1161/ATVBAHA.115.305460. View

19.

Lonardo A, Suzuki A . Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med. 2020; 9(5). PMC: 7288212. DOI: 10.3390/jcm9051278. View

20.

Tangpricha V, den Heijer M . Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2016; 5(4):291-300. PMC: 5366074. DOI: 10.1016/S2213-8587(16)30319-9. View